N 
Nanjing King-friend Biochemical Pharmaceutical Co 603707.SS · CNY
Health Care · Shanghai · 🇨🇳 China
8.75
-1.46%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in CNY, from our data supplier.
Revenue
CN¥3.99bn
FY2016FY2025
Net income
CN¥581.5m
FY2016FY2025
Free cash flow
CN¥622.6m
FY2016FY2025
Shareholders' equity
CN¥6.90bn
FY2016FY2025
Income statement
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | CN¥3.99bn | CN¥3.92bn | CN¥3.93bn | CN¥3.71bn | CN¥3.69bn | CN¥2.91bn | CN¥2.47bn | CN¥1.70bn | CN¥1.11bn | CN¥581.9m |
| Gross profit | CN¥1.82bn | CN¥1.81bn | CN¥659.1m | CN¥1.93bn | CN¥2.08bn | CN¥1.68bn | CN¥1.27bn | CN¥840.4m | CN¥516.0m | CN¥244.9m |
| Research and development | CN¥348.1m | CN¥329.9m | CN¥372.3m | CN¥263.7m | CN¥221.0m | CN¥187.5m | CN¥166.3m | CN¥101.2m | CN¥77.2m | CN¥49.0m |
| Operating income | CN¥738.6m | CN¥994.3m | −CN¥332.3m | CN¥1.02bn | CN¥1.23bn | CN¥928.0m | CN¥672.4m | CN¥451.4m | CN¥341.3m | CN¥144.2m |
| Net income | CN¥581.5m | CN¥826.1m | −CN¥189.4m | CN¥1.09bn | CN¥1.06bn | CN¥806.1m | CN¥605.0m | CN¥424.5m | CN¥314.2m | CN¥257.2m |
| Diluted earnings per share | 0.36 | 0.49 | -0.12 | 0.68 | 0.69 | 0.66 | 0.49 | 0.35 | 0.27 | 0.25 |
Balance sheet
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | CN¥10.34bn | CN¥9.51bn | CN¥9.52bn | CN¥10.01bn | CN¥8.22bn | CN¥7.72bn | CN¥5.08bn | CN¥3.40bn | CN¥2.69bn | CN¥1.52bn |
| Cash and short-term investments | — | CN¥2.08bn | CN¥1.89bn | CN¥1.39bn | CN¥918.4m | CN¥1.34bn | CN¥420.8m | CN¥434.8m | CN¥73.1m | CN¥265.7m |
| Total liabilities | CN¥3.44bn | CN¥3.02bn | CN¥3.73bn | CN¥3.84bn | CN¥2.81bn | CN¥3.98bn | CN¥2.07bn | CN¥981.2m | CN¥642.5m | CN¥208.1m |
| Debt | CN¥18.0m | CN¥2.06bn | CN¥2.09bn | CN¥2.96bn | CN¥2.05bn | CN¥3.26bn | CN¥1.37bn | CN¥319.9m | CN¥322.9m | CN¥120.0m |
| Shareholders' equity | CN¥6.90bn | CN¥6.49bn | CN¥5.80bn | CN¥6.17bn | CN¥5.38bn | CN¥3.72bn | CN¥2.97bn | CN¥2.42bn | CN¥2.05bn | CN¥1.31bn |
| Shares outstanding | 1,616m | 1,673m | 1,615m | 1,615m | 1,543m | 1,223m | 1,234m | 1,217m | 1,149m | 1,029m |
Cash flow
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | CN¥1.18bn | CN¥1.50bn | CN¥1.62bn | CN¥595.4m | CN¥683.6m | −CN¥565.8m | −CN¥841.4m | CN¥62.4m | −CN¥234.6m | −CN¥286.8m |
| Capital spending | −CN¥560.2m | −CN¥506.8m | −CN¥419.1m | −CN¥470.1m | −CN¥440.8m | −CN¥294.4m | −CN¥115.4m | −CN¥82.8m | −CN¥81.1m | −CN¥72.5m |
| Free cash flow | CN¥622.6m | CN¥994.4m | CN¥1.20bn | CN¥125.4m | CN¥242.9m | −CN¥860.2m | −CN¥956.8m | −CN¥20.4m | −CN¥315.7m | −CN¥359.3m |
| Dividends paid | −CN¥218.4m | −CN¥213.2m | −CN¥248.5m | −CN¥186.6m | −CN¥140.4m | −CN¥215.6m | −CN¥82.9m | −CN¥73.1m | −CN¥3.0m | −CN¥37.9m |
Latest quarters
By quarter end
| Jun 2026 | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | CN¥997.6m | CN¥928.7m | CN¥1.06bn | CN¥945.9m | CN¥1.09bn | CN¥885.2m | CN¥835.6m | CN¥945.4m |
| Gross profit | CN¥346.9m | CN¥300.0m | CN¥417.5m | CN¥412.9m | CN¥487.0m | CN¥304.6m | CN¥532.8m | CN¥416.6m |
| Operating income | CN¥81.8m | CN¥101.6m | CN¥149.3m | CN¥155.6m | CN¥219.2m | CN¥92.7m | CN¥285.1m | CN¥249.5m |
| Net income | CN¥98.5m | CN¥89.0m | CN¥152.1m | CN¥143.2m | CN¥201.6m | CN¥84.7m | CN¥220.4m | CN¥200.8m |
| Diluted earnings per share | 0.06 | 0.06 | 0.09 | 0.09 | 0.12 | 0.05 | 0.13 | 0.12 |
| Cash from operations | — | — | — | CN¥502.0m | CN¥246.0m | CN¥175.0m | — | CN¥425.0m |
| Capital spending | −CN¥104.0m | −CN¥37.0m | −CN¥189.0m | −CN¥18.0m | −CN¥143.0m | −CN¥208.0m | −CN¥82.0m | −CN¥152.0m |
| Free cash flow | — | — | — | CN¥484.0m | CN¥103.0m | −CN¥33.0m | — | CN¥273.0m |
| Total assets | CN¥10.88bn | CN¥10.69bn | CN¥10.34bn | CN¥10.31bn | CN¥9.69bn | CN¥8.93bn | CN¥9.51bn | CN¥9.43bn |
| Cash and short-term investments | — | — | — | CN¥2.70bn | CN¥1.96bn | CN¥1.43bn | CN¥2.08bn | CN¥1.95bn |
| Debt | CN¥18.0m | CN¥18.0m | CN¥18.0m | CN¥2.04bn | CN¥1.50bn | CN¥1.47bn | CN¥2.05bn | CN¥2.29bn |
| Shareholders' equity | CN¥6.94bn | CN¥6.99bn | CN¥6.90bn | CN¥6.75bn | CN¥6.61bn | CN¥6.58bn | CN¥6.49bn | CN¥6.27bn |
Financial ratios
Data as of 30 Sept 2026
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|
| Gross margin | 45.5% | 46.2% | 16.8% | 52.1% | 56.5% | 57.6% |
| Operating margin | 18.5% | 25.3% | -8.5% | 27.5% | 33.4% | 31.8% |
| Net margin | 14.6% | 21.1% | -4.8% | 29.4% | 28.7% | 27.7% |
| Return on equity | 8.4% | 12.7% | -3.3% | 17.7% | 19.7% | 21.7% |
| Return on assets | 5.6% | 8.7% | -2.0% | 10.9% | 12.9% | 10.4% |
| Free cash flow yield | 13.2% | 14.7% | 15.4% | 8.1% | 8.9% | -2.7% |
| Revenue growth | 1.7% | -0.2% | 5.9% | 0.7% | 26.5% | 18.0% |
| Earnings growth | -29.6% | -536.1% | -117.4% | 3.0% | 31.4% | 33.3% |
| Current ratio | 2.35x | 3.41x | 2.35x | 3.07x | 3.06x | 2.41x |
| Debt to equity | 0.00x | 0.32x | 0.36x | 0.48x | 0.38x | 0.88x |
| Equity ratio | 66.7% | 68.3% | 60.9% | 61.6% | 65.4% | 48.2% |
| Interest coverage | 13.37x | 12.74x | -4.10x | 17.12x | 13.08x | 15.28x |
| R&D as a share of sales | 8.7% | 8.4% | 9.5% | 7.1% | 6.0% | 6.4% |
| Buybacks as a share of market value | 3.4% | -3.6% | -0.0% | -4.7% | -26.1% | 0.8% |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | 2.4% | 6.5% | 23.9% |
| Operating income | -10.2% | -4.5% | 22.3% |
| Net income | -18.9% | -6.3% | 20.8% |
Average margins
Over each period
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Gross margin | 45.8% | 40.0% | 45.0% | 45.5% |
| Operating margin | 21.9% | 15.6% | 20.7% | 22.1% |
| Net margin | 17.8% | 14.8% | 18.8% | 20.6% |
Valuation history
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Price to earnings | 25.1 | 26.9 | -127.9 | 26.7 | 47.1 | 31.6 | 38.5 | 18.8 | 27.8 |
| Price to sales | 3.7 | 5.7 | 6.2 | 7.8 | 13.5 | 8.7 | 9.4 | 4.7 | 7.8 |
Dividends and splits
Per share, in the currency the company pays
Paid for 8 years. Last went ex-dividend on 9 Jun 2026.
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Paid in the year | 0.10 | 0.10 | 0.10 | 0.115 | 0.15 | 0.089 | 0.178 | 0.053 |
- 13-for-10 split · 11 Jul 2022
- 13-for-10 split · 15 Jul 2021
- 13-for-10 split · 23 Jul 2020
- 13-for-10 split · 10 Jul 2019
- 13-for-10 split · 3 Apr 2018
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.